{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:42Z","timestamp":1792831062930,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40265-026-02378-y","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:40:36Z","timestamp":1788511236000},"page":"1929-1934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pivekimab Sunirine: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1028-8594","authenticated-orcid":false,"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"8","key":"2378_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","volume":"2","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y, Jones GE, Adams S, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848\u201358.","journal-title":"Blood Adv"},{"key":"2378_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032718","author":"E Pelosi","year":"2023","unstructured":"Pelosi E, Castelli G, Testa U. CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24032718.","journal-title":"Int J Mol Sci"},{"key":"2378_CR3","unstructured":"AbbVie I. DECNUPAZTM (pivekimab sunirine-pvzy) for injection, for intravenous use: US prescribing information. 2026. https:\/\/www.rxabbvie.com\/pdf\/decnupaz.pdf. Accessed 10 Aug 2026."},{"key":"2378_CR4","unstructured":"AbbVie. U.S. FDA Approves DECNUPAZ(Tm) (pivekimab sunirine-pvzy) for treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer with limited treatment options [media release]. 27 May 2026. http:\/\/www.abbvie.com."},{"key":"2378_CR5","unstructured":"ImmunoGen. Annual report (Form 10-K) for the fiscal year ended December 31, 2022. 2023. https:\/\/www.sec.gov\/Archives\/edgar\/data\/855654\/000155837023002558\/imgn-20221231x10k.htm. Accessed 10 Aug 2026."},{"key":"2378_CR6","unstructured":"AbbVie. AbbVie completes acquisition of Immunogen [media release]. 12 Feb 2024. http:\/\/www.abbvie.com."},{"key":"2378_CR7","unstructured":"ImmunoGen. ImmunoGen announces clinical collaboration with Gilead to evaluate pivekimab sunirine in combination with magrolimab in relapsed\/refractory acute myeloid leukemia [media release]. 9 Dec 2022. http:\/\/www.immunogen.com."},{"key":"2378_CR8","unstructured":"Gilead Sciences. Gilead statement on discontinuation of phase 3 ENHANCE-3 study in AML [media release]. 7 Feb 2024. https:\/\/www.gilead.com\/."},{"issue":"5","key":"2378_CR9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41375-025-02571-0","volume":"39","author":"FM Cole","year":"2025","unstructured":"Cole FM, Laszlo GS, Lunn-Halbert MC, et al. Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632). Leukemia. 2025;39(5):1243\u20136.","journal-title":"Leukemia"},{"issue":"4","key":"2378_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3324\/haematol.2018.205252","volume":"104","author":"E Angelova","year":"2019","unstructured":"Angelova E, Audette C, Kovtun Y, et al. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019;104(4):749\u201355.","journal-title":"Haematologica"},{"issue":"e70063","key":"2378_CR11","first-page":"1","volume":"9","author":"B Watts","year":"2025","unstructured":"Watts B, Smith CM, Evans K, et al. The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia. Hemasphere. 2025;9(e70063):1\u201313.","journal-title":"Hemasphere"},{"issue":"3","key":"2378_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG, Montesinos P, DeAngelo DJ, et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol. 2024;25(3):388\u201399.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2378_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1200\/JCO-25-02083","volume":"44","author":"N Pemmaraju","year":"2026","unstructured":"Pemmaraju N, Marconi G, Montesinos P, et al. Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2026;44(10):861\u201373.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2378_CR14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2025-651","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Advani A, Burguera AD, et al. Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed acute myeloid leukemia [abstract]. Blood. 2025;146(Suppl 1):651\u20132.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02378-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02378-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02378-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:12:03Z","timestamp":1792829523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02378-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02378-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}